Search by Drug Name or NDC
NDC 72974-0415-01 Myfembree 1; .5; 40 mg/1; mg/1; mg/1 Details
Myfembree 1; .5; 40 mg/1; mg/1; mg/1
Myfembree is a ORAL TABLET, FILM COATED in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Sumitomo Pharma America, Inc. The primary component is ESTRADIOL HEMIHYDRATE; NORETHINDRONE ACETATE; RELUGOLIX.
Product Information
| NDC | 72974-0415 |
|---|---|
| Product ID | 72974-415_450384fa-4960-4f5b-8c7d-3ed6360dd1d3 |
| Associated GPIs | 24993503800320 |
| GCN Sequence Number | 082317 |
| GCN Sequence Number Description | relugolix/estradiol/norethindr TABLET 40-1-0.5MG ORAL |
| HIC3 | P1R |
| HIC3 Description | LHRH (GNRH) ANTAGONIST,ESTROGEN AND PROGESTIN COMB |
| GCN | 49699 |
| HICL Sequence Number | 047392 |
| HICL Sequence Number Description | RELUGOLIX/ESTRADIOL/NORETHINDRONE ACETATE |
| Brand/Generic | Brand |
| Proprietary Name | Myfembree |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | relugolix, estradiol hemihydrate, and norethindrone acetate |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | TABLET, FILM COATED |
| Route | ORAL |
| Active Ingredient Strength | 1; .5; 40 |
| Active Ingredient Units | mg/1; mg/1; mg/1 |
| Substance Name | ESTRADIOL HEMIHYDRATE; NORETHINDRONE ACETATE; RELUGOLIX |
| Labeler Name | Sumitomo Pharma America, Inc |
| Pharmaceutical Class | Breast Cancer Resistance Protein Inhibitors [MoA], Cytochrome P450 2B6 Inducers [MoA], Cytochrome P450 3A Inducers [MoA], Decreased GnRH Secretion [PE], Estradiol Congeners [CS], Estrogen Receptor Agonists [MoA], Estrogen [EPC], Gonadotropin Releasing Hor |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA214846 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 72974-0415-01 (72974041501)
| NDC Package Code | 72974-415-01 |
|---|---|
| Billing NDC | 72974041501 |
| Package | 28 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (72974-415-01) |
| Marketing Start Date | 2021-05-26 |
| NDC Exclude Flag | N |
| Pricing Information | |
| Price Per Unit | 40.1348 |
| Pricing Unit | EA |
| Effective Date | 2023-12-30 |
| NDC Description | MYFEMBREE 40 MG-1 MG-0.5 MG TB |
| Pharmacy Type Indicator | C/I |
| OTC | N |
| Explanation Code | 4 |
| Classification for Rate Setting | B |
| As of Date | 2024-02-21 |
This pricing file, entitled the NADAC (National Average Drug Acquisition
Cost) files, provide
state Medicaid agencies with covered outpatient drug prices by averaging
survey invoice
prices from retail community pharmacies across the United States. These
pharmacies include
independent retail community pharmacies and chain pharmacies. The prices
are updated on a
weekly and monthly basis